Development and Role in Therapy of Canakinumab in Adult-Onset Still&apos;s Disease by Galozzi, P et al.
fphar-09-01074 September 20, 2018 Time: 17:21 # 1
MINI REVIEW
published: 21 September 2018
doi: 10.3389/fphar.2018.01074
Edited by:
Stefania Tacconelli,
Università degli Studi “G. d’Annunzio”
Chieti – Pescara, Italy
Reviewed by:
Annalisa Chiavaroli,
Università degli Studi “G. d’Annunzio”
Chieti – Pescara, Italy
Anna Shcherbina,
Dmitry Rogachev National Research
Center of Pediatric Hematology,
Oncology and Immunology, Russia
*Correspondence:
Paolo Sfriso
paolo.sfriso@unipd.it
Specialty section:
This article was submitted to
Inflammation Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 12 June 2018
Accepted: 05 September 2018
Published: 21 September 2018
Citation:
Galozzi P, Baggio C, Bindoli S,
Oliviero F and Sfriso P (2018)
Development and Role in Therapy
of Canakinumab in Adult-Onset Still’s
Disease. Front. Pharmacol. 9:1074.
doi: 10.3389/fphar.2018.01074
Development and Role in Therapy of
Canakinumab in Adult-Onset Still’s
Disease
Paola Galozzi, Chiara Baggio, Sara Bindoli, Francesca Oliviero and Paolo Sfriso*
Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Adult-onset Still’s disease (AOSD) is a rare inflammatory disease of unknown etiology
typically characterized by episodes of spiking fever, evanescent rash, arthralgia,
leukocytosis, and hyperferritinemia. The pivotal role of interleukin (IL)-1 and other
pro-inflammatory cytokines gives rise to the development of new targeted therapies.
Currently, AOSD patients can benefit from efficient and well tolerated biologic agents,
such as IL-1, IL-6, and tumour necrosis factor (TNF)-α antagonists. Canakinumab,
a human monoclonal anti-IL-1β antibody, is indicated for the treatment of different
autoinflammatory syndromes in adults, adolescents, and children and it has recently
been approved for AOSD treatment. In this article, we summarize the structural and
biochemical data describing the molecular interactions between Canakinumab and
its target antigen. Some special considerations of the pharmacological properties of
Canakinumab are included. We also review the safety, efficacy and tolerability of this
drug for the treatment of AOSD.
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INTRODUCTION
Adult onset Still’s disease (AOSD) is a rare autoinflammatory disorder of unknown etiology
characterized by high spiking fever, salmon-like evanescent rash, and joint involvement. Other
symptoms are usually reported in AOSD, such as pharyngitis, myalgia, splenomegalia, hepatitis,
and abdominal pain (Kadavath and Efthimiou, 2015; Sfriso et al., 2016). The disease is very
heterogeneous, ranging from benign forms to severe life-threatening complications, such as
macrophage activation syndrome (MAS). Also the laboratory findings are highly unspecific.
High levels of C-reactive protein (CRP), increased erythrocyte sedimentation rate (ESR), blood
neutrophilia, hyperferritinemia, and elevated liver enzymes.
Adult-onset Still’s disease is a very uncommon disease, with an annual incidence estimated
between 0.16 and 0.62 per 100,000 persons worldwide, independent of ethnic group (Magadur-
Joly et al., 1995; Wakai et al., 1997; Evensen and Nossent, 2006; Balci et al., 2015). Recent
epidemiologic data from the Northwestern Thrace Region in Turkey reported an overall prevalence
of 6.77/100,000 between 2003 and 2014 (Balci et al., 2015), consistent with Norwegian point
prevalence data of 6.9/100,000 in 2000 (Evensen and Nossent, 2006). A Japanese nationwide survey
reported, on the other hand, an estimated prevalence of 3.9/100,000 in 2010/2011 (Asanuma et al.,
2015).
In light of new evidence, a dichotomous classification distinguishes two AOSD subtypes
according to clinical evolution: a systemic subtype, including patients with systemic features
and more at risk to develop life-threatening complications, and a subtype where patients have
predominantly articular involvement (Maria et al., 2014).
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Adult-onset Still’s disease shares common clinical and
biological features with another systemic inflammatory
condition, called systemic onset Juvenile Idiopathic Arthritis
(SoJIA), affecting children aged 16 years or younger (Jamilloux
et al., 2015). This supports the concept of a Still’s disease
continuum that includes both the juvenile onset (SoJIA) and
adult onset (AOSD) form. Evidence also suggests that both
diseases are comparable at the molecular level, probably due to
the activation of similar inflammatory pathways. Nirmala et al.
(2015) showed that most genes upregulated following a specific
treatment in SoJIA patients were downregulated in the majority
of AOSD patients.
The pathogenic mechanisms leading to AOSD and SoJIA are
complex and not fully understood. An abnormal activation of
the innate immune response is observed and several data sustain
the pivotal role of inflammatory cytokines, in particular high
levels of interleukin (IL)-1β, IL-6, IL-8, and tumour necrosis
factor (TNF)-α (Maria et al., 2014; Sfriso et al., 2018). Thus, in
addition to the classic therapeutic options (non-steroidal anti-
inflammatory drugs (NSAIDs), steroids, and immunosuppressive
drugs), biologic agents targeting proinflammatory cytokines may
be an effective approach.
The IL-1 inhibitors (anakinra, rilonacept, and canakinumab;
Figure 1A) are actively used in both AOSD and SoJIA
(Giampietro and Fautrel, 2012). Anakinra is the non-glycosylated
recombinant soluble antagonist of the IL-1 receptor (IL-1R) that
acts preventing activation of this receptor and inhibiting both IL-
1α and IL-1β activity. Rilonacept (IL-1 TRAP) is a recombinant
chimeric protein composed of an extracellular domain of the
human IL-1R complex fused to the Fc-portion of human IgG1.
This protein is able to bind IL-1α and IL-1β with high affinity.
Canakinumab is a recombinant human monoclonal antibody
specifically targeting IL-1β (Astrakhantseva et al., 2014).
Previous review articles focused primarily on Anakinra, but
new as well as updated data for Canakinumab have emerged with
regard to the treatment not only of SoJIA but also of AOSD
(Hong et al., 2014; Rossi-Semerano et al., 2015; Colafrancesco
et al., 2017; Feist et al., 2018).
In this study, we summarize the initial steps of the
development and the particular pharmacological characteristics
of Canakinumab, reviewing currently available data on its use in
the clinical setting, focusing on AOSD.
DESIGN AND DEVELOPMENT OF
CANAKINUMAB
Among the proinflammatory cytokines, the interleukin-1 family
and IL-1β in particular play a central role in immune response
regulation and in the development of inflammation in Still’s
disease (Dinarello, 2011). IL-1β is synthesized as inactive
precursors, and the processing of pro-IL-1β is dependent on
proteolytic cleavage by caspase-1, which itself is activated by
a multi-protein complex called the inflammasome. A signal
from IL-1 cytokine family is transduced via specific receptors
(IL-1Rs) composed of an extracellular immunoglobulin-like
domain that wraps around the cytokine and a Toll/IL-1 receptor
(TIR) domain essential for signaling. Among the two types
of IL-1Rs, type I IL-1R (IL-1RI) binds IL-1β with higher
affinity than type II (IL-1RII). The complex IL-1β/IL-1RI results
in a conformational change of the receptor that allows the
binding with IL-1RAcP, a second receptor subunit (Wang et al.,
2010; Rondeau et al., 2015). The structures of the ternary
complexes of IL-1β with IL-1RAcP and IL-1RII or IL-1RI
present a large binding interface between IL-1β and IL-1RI
or IL-1RII, and a small surface of interaction with IL-1RAcP,
facilitating interaction with receptor chains (Rondeau et al.,
2015). This complex triggers a signaling cascade resulting in
the activation of the NF-κB and MAPK pathways (Figure 1B;
Auron, 1998; Dunne and O’Neill, 2003; Martin and Bugelski,
2012).
Downregulation of IL-1β activity can be achieved in two
different ways. Interleukin-1 receptor antagonist (IL-1RA) can
bind directly to IL-1RI preventing IL-1β and IL-1α from initiating
the signal transduction or a decoy receptor, such as IL-1RII can
inhibit the inflammatory response binding IL-1β, avoiding the
excess of autocrine activation of the IL-1 signal.
Neutralization of the IL-1β bioactivity by an antibody
targeting this cytokine could be achieved by interference with
the binding of IL-1β to IL-1RI, or with the interaction between
IL-1β and IL-1RAcP, or with the recruitment of IL-1RAcP into
the IL-1β/IL-1RI complex (Vigers et al., 1994; Dinarello, 1998;
Thomas et al., 2012; Rondeau et al., 2015). Canakinumab was
generated using HuMab-Mouse TM technology from Medarex
(UltiMab technology). HuMab mice are transgenic mice designed
to produce fully human antibodies since their endogenous
immunoglobulin repertoire is inactivated by targeted genetic
disruption. These mice produce human IgG1 antibodies upon
immunization with antigen, and human monoclonal antibodies
are derived by conventional hybridoma technology (Fishwild
et al., 1996; Lonberg, 2005; Gram, 2016). The supernatants
from the hybridomas were evaluated using an ELISA screening
method to determine the specificity and affinity of these
antibodies, resulting ultimately in the selection of Canakinumab,
a human IgG1/k antibody (Canakinumab Patent Application
WO02/16436).
The molecular formula for Canakinumab is based on the
amino acid composition without post-translational glycosylation
but including N-terminal pyroglutamate formation and lysine
residues at the C-terminals of the heavy chains (European
Medicines Agency [EMA], 2017). Both heavy chains of
Canakinumab contain oligosaccharide chains linked to the
protein backbone at Asparagine (Asn) 298 (Dhimolea, 2010).
The X-ray structure of IL-1β/Canakinumab complex revealed
that Glutamic acid (Glu) 64 in human IL-1β is a critical
residue for this interaction. Canakinumab has high selectivity
toward human IL-1β, assessed by competitive binding studies
with soluble IL-1 receptors (Canakinumab Patent Application
WO02/16436). Thus, it does not bind to other members of the IL-
1 family (Figure 2A). Several in vitro studies have reported that
Canakinumab interacts with human IL-1β with an equilibrium
binding constant of about 40 pM and neutralizes the biological
activity of IL-1β in vivo with an IC50 of about 43 pM (Alten et al.,
2008; Rondeau et al., 2015).
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FIGURE 1 | Mode of action of IL-1 and its inhibitors. (A) The IL-1 inhibitors (anakinra, rilonacept, and canakinumab). Anakinra (on the left) competes with free IL-1β
for the binding with IL-1RI but not with the adaptor protein, thus preventing signal transduction. Rilonacept (in the middle) and Canakinumab (on the right) bind to
circulating IL-1β. (B) Binding of IL-1β to the IL-1 receptor type I (IL-1RI) heterodimer complex results in signal transduction. IL-1β binds to the membrane-bound
IL-1RI to form a complex with the IL-1 receptor accessory protein (IL-1RAcP). This complex recruits the IL-1RI-associated kinase (IRAK), leading to signal
transduction and gene activation.
Canakinumab also has a high degree of species specificity.
It does not bind to IL-1β from macaques, rodents, canines,
and many other mammalian species, since the critical residue
Glu 64 is not conserved in these species (Rondeau et al.,
2015). Nevertheless, the same authors identified marmosets
as the only non-human primate species that carries Glu 64
in its IL-1β (like the human IL-1β) and demonstrated full
cross-reactivity of Canakinumab, thereby enabling toxicological
studies in this species. No toxicologically significant findings
were detected (Martin and Bugelski, 2012). An embryo-fetal
development study conducted in marmosets showed no major
malformations but some slight skeletal variations at all dose
levels of Canakinumab were suggestive of a delay in skeletal
development.
Due to its high affinity and specificity for IL-1β, Canakinumab
was considered suitable for therapeutic applications (Church and
McDermott, 2009). The biological activity of this agent has been
evaluated both in vitro and in animal models. The in vitro analysis
showed a complete inhibition of IL-6 secretion stimulated by IL-
1β in human dermal fibroblasts (Alten et al., 2008). Church and
McDermott (2009) assessed the neutralization of IL-1β activity
by Canakinumab in a mouse model of joint inflammation.
The treatment proved to provide protection against severe
joint destruction, with no bone erosion detected compared to
controls. Demonstration of pharmacodynamic action in vivo
was conducted in preclinical mouse model NIH 3T3. Dawson
and colleagues observed that systemic intraperitoneal injections
of Canakinumab in this model inhibit the neutrophil invasion
in a dose-dependent manner (Gram, 2016). Mouse models for
arthritis were used, instead, to validate the in vivo efficacy of
Canakinumab. Study results demonstrated that Canakinumab
can completely suppress IL-1β-mediated joint inflammation and
cartilage destruction in mice (Alten et al., 2008).
In order to elucidate the molecular mechanism by which
Canakinumab interferes with the IL-1β, Rondeau et al.
(2015) determined the crystal structures of the Canakinumab
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FIGURE 2 | (A) Steric complementarity between Canakinumab and IL-1β.
Canakinumab (gray) binding to IL-1β (blues) largely obeys a lock-and-key type
mechanism, with contributions by all CDRs and without any large structural
changes of the paratope. (B,C) Hydrophobic potential of Canakinumab’s Fab
heavy and light chain. The surfaces are colored according to amino acid
hydrophobicity. The hydrophobic residues (larger positive values of
hydrophobicity) are maroon, while the hydrophilic residues (negative values of
hydrophobicity) are cyan. The binding interface is remarkably flat, extensively
hydrated, and very large. The IL-1β epitope does not include any aromatic or
bulky hydrophobic residues. (2 B) surface epitope; (2 C) surface paratope.
(D) All kind of interactions (polar and no polar, favorable) between
Canakinumab and IL-1β. The paratope residues that stand out in terms of
number of intermolecular contacts to IL-1β are colored in yellow: Arginine
(Arg) H101, Tryptophan (Trp) H52, Tyrosine (Tyr) H53, Tyr H32 and Tyr L50. Arg
H101 of the H-CDR3 loop plays an important role by forming strong
electrostatic interactions with the epitope residue Glutamic acid (Glu) 64
(orange). Lysine (Lys) 27 (green) forms salt-bridge interactions.
Fab in the free and IL-1β-bound states. Canakinumab Fab
subunits adopt the immunoglobulin fold and recognizes an
extended, discontinuous epitope on human IL-1β. The binding
interface is flat, hydrated, and very large (Figures 2B,C). The
X-ray analysis conducted by Rondeau et al. (2015) reveals a
complex surface epitope with ordered water molecules at the
Canakinumab-antigen interface. These molecules contribute to
the H-bonded network that connects epitope and paratope
residues mediating shape/physico-chemical complementarity,
improving the packing of atoms and allowing polar interactions.
The amino acid composition of the paratope site is a balanced
mix of hydrophobic aromatic, hydrophobic aliphatic, polar, and
charged residues (Blech et al., 2013; Rondeau et al., 2015).
The IL-1β epitope forms an extended, mostly planar, and
hydrophilic surface (70% of all residues are polar or charged
amino-acids). The combination of electrostatic interaction and
shape complementarity plays a key role in the formation
of the complex between Canakinumab and IL-1β. Epitope
residues engaged in direct contacts with paratope form either
direct H-bonded contacts with Canakinumab or salt-bridge
interactions. The epitope residues that contribute the largest
number of contacts are Glu 64 that is connected to 4 CDRs,
Gln 38, Lys 65, Asp 35, and Ser 258 (Figure 2D; Blech et al.,
2013; Rondeau et al., 2015). Also, several induced-fit changes
were observed at the binding interface.
The neutralizing effect of Canakinumab is caused by the
direct competition for cytokine binding. There are no direct
interactions between Canakinumab and IL-1RAcP. It was
observed that Canakinumab and IL-1RI binding sites slightly
overlap; the VH region of Canakinumab, indeed, sterically
interfere with a domain of IL-1RI (Blech et al., 2013; Rondeau
et al., 2015).
THERAPY
Considering the rarity of AOSD, the majority of the data
on treatment management derive from empirical observations
through case reports and small series, which are not standardized
and may underrate the number of cases treated. Controlled
clinical trials comparing the efficacies of various agents or the
usefulness of different therapeutic strategies are lacking.
In order to identify the most appropriate individualized
therapeutic strategy for AOSD patients, Govoni et al. (2017)
recently suggested taking into consideration the following factors:
the disease phase (onset, maintenance, flares), the ongoing
predominant clinical features (systemic or articular) and the
presence/absence of complications.
In general, the first-line treatments consist of NSAIDs and
corticosteroids. In case of failure or dependence of these agents,
immunosuppressive drugs such as cyclosporine A, azathioprine,
leflunomide, hydroxychloroquine, methotrexate can be used
(Maria et al., 2014). There is increasing evidence on the usefulness
of biologic therapies in the management of corticosteroid
and DMARD-refractory AOSD, reported in case series and/or
national surveys (Fautrel et al., 2005; Franchini et al., 2010;
Gerfaud-Valentin et al., 2014; Colafrancesco et al., 2017). The
rationale for the use of biologics, actually targeting cytokines, lies
in increased knowledge about the pathophysiology of the disease.
Anti-TNF-α may be an attractive therapeutic option in AOSD
with a predominant articular pattern (Gerfaud-Valentin et al.,
2014), while IL-1β inhibitors are more effective for the systemic
manifestations (Vitale et al., 2016). The use of an IL-6 antagonist
has proved to be useful for both joint and systemic manifestations
(Cipriani et al., 2014).
There are also no guidelines for decisions about how long
to continue biologics, once clinical remission is achieved. In
patients with systemic AOSD, response to IL-1 inhibitors must
be expected within hours or days; in the articular subset, the
response to anti IL-6 or anti-TNF may require more time, but
the low disease activity should be achieved within no more than
3 months. If clinical remission is maintained for at least 6–
12 months, a cautious attempt to taper the biologic could be
pursued (Govoni et al., 2017).
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Like in SoJIA and other autoinflammatory diseases, targeting
IL-1β seems particularly relevant in AOSD, in agreement with the
several case series and national surveys on it (see Junge et al., 2017
for a comprehensive review).
Canakinumab is indicated for the treatment of different
autoinflammatory syndromes in adults, adolescents and
children aged 2 years and older. In 2009, it was approved by
the United States Food and Drug Administration (FDA) for
the treatment of cryopyrin-associated periodic syndromes
(CAPS) and active systemic juvenile idiopathic arthritis
(SoJIA). In 2013, the European Commission approved
Canakinumab for adult patients with frequent gouty arthritis
attacks. In 2016, the FDA approved expanded indications
for tumour necrosis factor receptor associated periodic
syndrome (TRAPS), mevalonate kinase deficiency (MKD),
familial Mediterranean fever (FMF) in combination with
colchicine. In 2016, the EMA also approved Canakinumab
for a license extension to treat patients with Adult-onset
Still’s disease (AOSD), supported by the concept of a Still’s
disease continuum that includes both juvenile and adult
onset forms (Nirmala et al., 2015). The population-based
pharmacokinetics-binding model of Still’s disease by Feist et al.
(2018) showed that Canakinumab exposure is comparable across
all ages.
Sun et al. (2016) characterized the pharmacokinetic (PK) and
pharmacodynamic (PD) properties of Canakinumab in SoJIA
patients aged under 20, to evaluate adequacy of exposure of
the drug and the recommended dosage in the population.
TABLE 1 | Reports of Canakinumab use in AOSD patients.
Reports # Patients and dosage Results
Kontzias and Efthimiou, 2012 n. 2 patients with refractory AOSD received 150 mg of
Canakinumab s.c. injections every 8 weeks
– Resolved systemic symptoms,
– normalized laboratory values,
– no AEs (except transient diarrhea in 1 of 2 patients),
– no relapse in 6–12 months
Banse et al., 2013 n. 1 patient with refractory AOSD received two doses of
150 mg of Canakinumab s.c. injections per week
– Development of MAS after the second injection at 3
and 6 months after MAS,
– resolved symptoms and normalized laboratory values
Eriksson et al., 2013 n. 1 patient with refractory AOSD received 150 mg of
Canakinumab s.c. injections every 8 weeks
– Resolved joint and skin symptoms
– normalized laboratory values
Barsotti et al., 2014 n. 1 patient with refractory AOSD received 150 mg of
Canakinumab s.c. injections every 4 weeks, gradually
increasing up to 150 mg every 8 weeks
– Three brief episodes of fever, not temporally related to
Canakinumab
– no systemic and joint symptoms at 18 month
follow-up
Lo Gullo et al., 2014 n. 1 patient with refractory AOSD received 150 mg of
Canakinumab s.c. injections every 8 weeks
– No systemic symptoms at 14 month follow-up
– normalized laboratory values
– recurrent arthritis required methylprednisolone
12 mg/day
Maria et al., 2014 n. 1 patient with refractory AOSD received
Canakinumab (dosage not reported)
– Rapid and complete remission of systemic symptoms
at 30 month follow-up
Rossi-Semerano et al., 2015 A French nationwide survey includes n. 2 patients with
refractory AOSD receiving 150 mg of Canakinumab s.c.
injections every 4 and 8 weeks, respectively
– Complete remission in 1 patient receiving
150 mg/8 week
– no clinical improvement in 1 patient receiving
150 mg/4 week
Colafrancesco et al., 2017 An Italian nationwide survey includes n. 4 patients with
refractory AOSD receiving 150 mg of Canakinumab s.c.
injections every 8 weeks
– Normalized laboratory values
– effective in 3 out 4 patients
– loss of efficacy in 1 patient with chronic articular
AOSD
– no AEs
Feist et al., 2018 Pooled analyses from SoJIA studies (NCT00426218,
NCT00886769, NCT00889863, and NCT00891046)
include n. 29 older adolescents/young adults
(representing AOSD patients), receiving 4 mg/kg every
4 weeks
– At day 15, 19 out 29 older adolescents/young adults
have aACR ≥ 70 responses and showed
improvements (13 out 18) at day 85.
– Normalized laboratory values
Sinha et al., 2018 n. 1 patient with refractory AOSD and severe pulmonary
hypertension received Canakinumab (dosage not
reported)
– No clinical improvement
Trial NCT02204293 (Fase II) A 12-week trial including 68 AOSD patients randomized
into two groups receiving either placebo or 150 mg of
Canakinumab s.c. injections every 8 weeks. The aim of
the study is to assess the efficacy, safety, and
tolerability of Canakinumab
– The primary outcome measures will be available in
June 2019
s.c., sub-cutaneous; AOSD, Adult-onset Still’s disease; AEs, adverse events; MAS, macrophage activation syndrome; SoJIA, systemic onset juvenile idiopathic arthritis;
aACR, adapted American College of Rheumatology.
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A population-based PK-binding model was built to evaluate
Canakinumab PK properties and total IL-1β kinetic properties.
The model showed that Canakinumab clearance and volume of
distribution were not impacted by age after correction for the
patient’s body weight. Canakinumab exhibited dose-proportional
exposure with increasing doses in patients with SoJIA, as
expected. The pharmacokinetic modeling analysis also predicted
Canakinumab steady state after 110 day exposures at a dose level
of 4 mg/kg in SoJIA patients. These data would be comparable to
those in older SoJIA patients, who represent AOSD patients.
The recommended posology for patients with Still’s disease
(AOSD and SoJIA) with body weight ≥7.5 kg is 4 mg/kg (up
to a maximum of 300 mg) administered every 4 weeks via
subcutaneous injection (European Medicines Agency [EMA],
2017). Up to now, the use of Canakinumab has been reported
in 24 AOSD patients (Kontzias and Efthimiou, 2012; Banse
et al., 2013; Eriksson et al., 2013; Barsotti et al., 2014; Lo
Gullo et al., 2014; Maria et al., 2014; Rossi-Semerano et al.,
2015; Colafrancesco et al., 2017; Sinha et al., 2018) and 29
older adolescents/young adults representing AOSD patients
(Feist et al., 2018), refractory to NSAIDs, DMARDs and often
to other biologic therapy. The majority of patients showed a
rapid and sustained efficacy with subcutaneous injection of
150 mg every 8 weeks. All the reports and their results are
summarized in Table 1. Canakinumab was reported effective
in treating arthritic symptoms as well as systemic symptoms
in 9 out of 14 AOSD patients (Kontzias and Efthimiou,
2012; Banse et al., 2013; Eriksson et al., 2013; Barsotti
et al., 2014; Maria et al., 2014; Rossi-Semerano et al., 2015;
Colafrancesco et al., 2017). Of note, Lo Gullo et al. (2014)
reported a refractory case of AOSD in which Canakinumab
was efficient only for systemic manifestations, while joint
involvement remained active with high disease activity scores.
Moreover, the pooled analysis from SoJIA studies by Feist et al.
(2018) indicates that consistent clinical benefits, represented by
clinical and inflammatory laboratory markers and quality of
life (QoL) measures, observed in older adolescents and young
adults are comparable to those seen in children and young
adolescents.
In the listed reports (Table 1), Canakinumab was effective
in the most difficult-to-treat cases of refractory AOSD, except
in two patients (Rossi-Semerano et al., 2015; Sinha et al.,
2018). The former was a refractory AOSD patient with
a rare cardiopulmonary manifestation (severe pulmonary
hypertension), the latter was a refractory AOSD patient receiving
150 mg/4 week Canakinumab.
Overall, Canakinumab was well-tolerated and only two
adverse events (AEs) were reported (Kontzias and Efthimiou,
2012; Banse et al., 2013). One is a MAS, a serious AE suggested by
Banse et al. (2013) to be related to the drug, even though MAS is a
frequent complication of AOSD. The other is a transient diarrhea
in a good responder patient.
Interactions between Canakinumab and other drugs have not
been investigated in formal studies. An increased safety risk and
raised incidence of serious infections and injection-site reactions
have been associated with combination therapy of Anakinra and
TNF inhibitors in the treatment of patients with rheumatoid
arthritis (Genovese et al., 2004). Thus, the use of Canakinumab
with TNF inhibitors is not recommended because this may
increase the risk of serious infections.
Canakinumab has a well-established safety and efficacy
profile in SoJIA, as reported by recently published SoJIA
clinical trials (NCT00889863, NCT00886769, NCT00891046,
and NCT00426218) (Ruperto et al., 2012a,b; Sun et al., 2016).
Clinical endpoints such as ACR criteria, including adapted
American College of Rheumatology pediatric criteria (aACR)
responses, improved rapidly; at day 15, indeed, at least 50%
of patients, aged between 2 and 20 years, had aACR ≥ 70
responses and were maintained or improved over 12 weeks of
treatment. Interestingly, the pooled analysis from SoJIA patients
indicates that older adolescents exhibit similar efficacy, safety,
and exposure-response relationship on a weight-based dosing
regimen to children and adolescent SoJIA patients (Feist et al.,
2018).
Concerning AOSD, a multicentre, placebo-controlled clinical
trial (NCT02204293) is currently ongoing. The aim of this
interventional study is to investigate the efficacy of Canakinumab
in 68 patients with AOSD and active joint involvement in terms
of the proportion of patients with a clinically significant reduction
in disease activity (DAS28> 1.2) following a treatment period of
12 weeks.
Consistent with prior reports (Table 1), data on complete or
partial remission in most patients treated with Canakinumab also
emphasized the efficacy of this drug in AOSD. The initial efficacy
of Canakinumab seems not to be clearly different from that of
the other two IL-1 inhibitors. Both Anakinra and Rilonacept
indeed showed rapid and sustained efficacy (Henderson et al.,
2010; Hong et al., 2014), but it can be lost over time, reflecting
their shorter half-life (4–6 h and 9 days, respectively) compared to
that of Canakinumab (26 days) (Kontzias and Efthimiou, 2012).
Canakinumab is also better tolerated than the other IL-1
inhibitors (Henderson et al., 2010; Rossi-Semerano et al., 2015).
Beyond the common side-effects of Anakinra and Rilonacept
(injection site reactions), both agents presented few severe AEs.
Taken together, this substantial evidence endorses the use of
IL-1 inhibitors in AOSD patients refractory to other treatments,
even as early treatments (Pouchot and Arlet, 2012). Their ability
to interrupt the disease process suggested the possibility of
shortening flares and avoiding chronic relapses.
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